Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors

PURPOSE: TRX518 is a mAb engaging the glucocorticoid-induced TNF receptor−related protein (GITR). This open-label, phase I study (TRX518-003) evaluated the safety and efficacy of repeated dose TRX518 monotherapy and in combination with gemcitabine, pembrolizumab, or nivolumab in advanced solid tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Davar, Diwakar, Zappasodi, Roberta, Wang, Hong, Naik, Girish S., Sato, Takami, Bauer, Todd, Bajor, David, Rixe, Olivier, Newman, Walter, Qi, Jingjing, Holland, Aliya, Wong, Phillip, Sifferlen, Lianna, Piper, Diane, Sirard, Cynthia A., Merghoub, Taha, Wolchok, Jedd D., Luke, Jason J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475244/
https://www.ncbi.nlm.nih.gov/pubmed/35499569
http://dx.doi.org/10.1158/1078-0432.CCR-22-0339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475244/
https://www.ncbi.nlm.nih.gov/pubmed/35499569
http://dx.doi.org/10.1158/1078-0432.CCR-22-0339

Ejemplares similares